Amended Statement of Beneficial Ownership (sc 13d/a)
August 14 2020 - 4:41PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Eyenovia, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
30234E 104
(CUSIP Number)
Tsontcho Ianchulev
Curt LaBelle
295 Madison Avenue, Suite 2400
New York, NY 10017
917-289-1117
(Name, Address and Telephone Number of Person
Authorized to
Receive Notices and Communications)
August 13, 2020
(Date of Event which Requires Filing of
this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐
Note: Schedules filed in paper format
shall include a signed original and five copies of the schedule, including all exhibits. See section 240.13d-7 for other parties
to whom copies are to be sent.
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or other subject to the liabilities of that section of Act but shall be subject to all other provisions
of the Act (however, see the Notes).
(Page 1
of 7 Pages)
|
CUSIP No. 30234E 104
|
Page 2 of 7 Pages
|
|
1
|
Names of Reporting Persons.
Tsontcho Ianchulev
|
|
2
|
Check the Appropriate Box if a Member of
a Group
(a)
¨
(b)
¨
|
|
3
|
SEC Use Only
|
|
4
|
Source of Funds (See Instructions)
PF
|
|
5
|
Check
if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨
|
|
6
|
Citizenship or Place of Organization
|
|
|
|
|
|
United States
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7
|
Sole Voting Power
1,069,635(1)
|
|
8
|
Shared Voting Power
1,206,001(2)
|
|
9
|
Sole Dispositive Power
1,069,635(1)
|
|
10
|
Shared Dispositive Power
1,206,001(2)
|
|
11
|
Aggregate Amount Beneficially Owned by
Each Reporting Person
2,275,636(1)(2)
|
|
12
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
|
|
13
|
Percent of Class Represented by Amount
in Row (11)
10.7%
|
|
14
|
Type of Reporting Person
IN
|
|
|
|
|
|
|
|
(1)
|
Includes (i) 508,679 shares of common stock, (ii) 457,917 shares of common stock underlying options and (iii) 41,216 shares of common stock underlying Class A warrants and (iv) 61,823 shares of common stock underlying Class B warrants held by Tsontcho Ianchulev directly that are exercisable within 60 days of the date of this report.
|
|
|
(2)
|
Includes (i) 6,000 shares of common stock held by the Meliora Trust, (i) 606,667 shares of common stock and 140,000 shares of common stock underlying options held by Private Medical Equity, Inc. that are exercisable within 60 days of the date of this report and (ii) 453,334 shares of common stock held by PME Investor Services Eyenovia, LLC. Dr. Ianchulev and his wife are trustees and beneficiaries of the Meliora Trust. He is one of the two principal shareholders of Private Medical Equity, Inc. and a manager of PME Investor Services Eyenovia, LLC and, therefore, may be deemed to have beneficial ownership of the shares of common stock held by Private Medical Equity, Inc. and PME Investor Services Eyenovia, LLC.
|
|
CUSIP No. 30234E 104
|
Page 3 of 7 Pages
|
|
1
|
Names of Reporting Persons.
Curt LaBelle
|
|
2
|
Check the Appropriate Box if a Member of
a Group
(a)
¨
(b)
¨
|
|
3
|
SEC Use Only
|
|
4
|
Source of Funds (See Instructions)
PF
|
|
5
|
Check
if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨
|
|
6
|
Citizenship or Place of Organization
|
|
|
|
|
|
United States
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7
|
Sole Voting Power
217,661(1)
|
|
8
|
Shared Voting Power
1,200,001(2)
|
|
9
|
Sole Dispositive Power
217,661(1)
|
|
10
|
Shared Dispositive Power
1,200,001(2)
|
|
11
|
Aggregate Amount Beneficially Owned by
Each Reporting Person
1,417,662(1)(2)
|
|
12
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
|
|
13
|
Percent of Class Represented by Amount
in Row (11)
6.8%
|
|
14
|
Type of Reporting Person
IN
|
|
|
|
|
|
|
|
(1)
|
Includes 27,985 shares of common stock and 189,676 shares underlying options held by Curt LaBelle directly that are exercisable within 60 days of the date of this report.
|
|
|
(2)
|
Includes (i) 606,667 shares of common stock and 140,000
shares of common stock underlying options held by Private Medical Equity, Inc. that are exercisable within 60 days of the date
of this report and (ii) 453,334 shares of common stock held by PME Investor Services Eyenovia, LLC. Dr. LaBelle is one of the
two principal shareholders of Private Medical Equity, Inc. and a manager of PME Investor Services Eyenovia, LLC and, therefore,
may be deemed to have beneficial ownership of the shares of common stock held by Private Medical Equity, Inc. and PME Investor
Services Eyenovia, LLC.
|
|
CUSIP No. 30234E 104
|
Page 4 of 7 Pages
|
|
1
|
Names of Reporting Persons.
Private Medical Equity, Inc.
|
|
2
|
Check the Appropriate Box if a Member of
a Group
(a)
¨
(b)
¨
|
|
3
|
SEC Use Only
|
|
4
|
Source of Funds (See Instructions)
WC
|
|
5
|
Check
if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ¨
|
|
6
|
Citizenship or Place of Organization
|
|
|
|
|
|
Nevada
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7
|
Sole Voting Power
746,667(1)
|
|
8
|
Shared Voting Power
0
|
|
9
|
Sole Dispositive Power
746,667(1)
|
|
10
|
Shared Dispositive Power
0
|
|
11
|
Aggregate Amount Beneficially Owned by
Each Reporting Person
746,667(1)
|
|
12
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
|
|
13
|
Percent of Class Represented by Amount
in Row (11)
3.6%
|
|
14
|
Type of Reporting Person
CO
|
|
|
|
|
|
|
|
(1)
|
Includes 606,667 shares of common stock and 140,000 shares of common stock underlying options held by Private Medical Equity, Inc. that are exercisable within 60 days of the date of this report.
|
|
CUSIP No. 30234E 104
|
Page 5 of 7 Pages
|
SCHEDULE 13D
This Amendment No. 3 on Schedule 13D amends
the statement on Schedule 13D, dated February 14, 2018, which relates to the common stock, par value $0.0001 per share (the “Common
Stock”) of Eyenovia, Inc. (the “Issuer”), as previously amended on Schedule 13D/A, dated January 2, 2019 and
July 11, 2019 filed by:
Tsontcho Ianchulev
Curt LaBelle
Private Medical Equity, Inc.,
a Nevada corporation (“PME”)
(collectively, PME with Drs.
Ianchulev and LaBelle, the “Reporting Persons”).
This Amendment No.
3 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result
of the change in outstanding shares of Common Stock of the Issuer as reported by the Issuer in its Quarterly Report on Form 10-Q
for the period ended June 30, 2020, filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2020.
Except as expressly amended below, the Schedule 13D, dated February 14, 2018, which was previously amended on January 2 and July
11, 2019, remains in effect.
|
Item 3.
|
Source and Amount of Funds or Other Consideration.
|
On March 24, 2020, Dr. Ianchulev purchased
82,431 shares of Common Stock at a purchase price of $2.27 per share, and also received 41,216 Class A Warrants (defined below)
and 61,823 Class B Warrants (defined below) in the Issuer’s offering of approximately $6.0 million of units (the “Units”),
with each Unit consisting of (i) one share of the Issuer’s Common Stock, (ii) a one-year warrant to purchase 0.5 of a share
of the Issuer’s Common Stock (“Class A Warrant”), and (iii) a five-year warrant to purchase 0.75 of a share of
the Issuer’s Common Stock (“Class B Warrant”).
|
Item 4.
|
Purpose
of the Transaction
|
The shares of Common Stock owned by the
Reporting Persons have been acquired for investment purposes. The Reporting Persons may make further acquisitions of the Common
Stock from time to time and, subject to certain restrictions, may dispose of any or all of the Common Stock held by the Reporting
Persons at any time depending on an ongoing evaluation of the investment in such securities, prevailing market conditions, other
investment opportunities and other factors.
On March 24, 2020, Dr. Ianchulev purchased
82,431 shares of Common Stock, at a purchase price of $2.27 per share, and also received 41,216 Class A Warrants and 61,823 Class
B Warrants in the Issuer’s offering of approximately $6.0 million of Units, with each Unit consisting of (i) one share of
the Issuer’s Common Stock, (ii) a one-year Class A warrant to purchase 0.5 of a share of the Issuer’s Common Stock,
and (iii) a five-year Class B warrant to purchase 0.75 of a share of the Issuer’s Common Stock.
Except for the foregoing, the Reporting
Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through
(j) of Item 4 of this Amendment No. 3 to Schedule 13D.
|
Item 5.
|
Interest in Securities of the Issuer
|
(a)-(b) The aggregate number and percentage of Common
Stock beneficially owned by the Reporting Persons (on the basis of a total of 20,536,431 shares of Common Stock outstanding
as of August 13, 2020) are as follows:
Tsontcho Ianchulev
|
a)
|
|
Amount
beneficially owned: 2,275,636
|
|
Percentage:
10.7%
|
|
b)
|
|
Number
of shares to which the Reporting Person has:
|
|
|
|
|
i.
|
Sole
power to vote or to direct the vote:
|
|
1,069,635(1)
|
|
|
ii.
|
Shared
power to vote or to direct the vote:
|
|
1,206,001(2)
|
|
|
iii.
|
Sole
power to dispose or to direct the disposition of:
|
|
1,069,635(1)
|
|
|
iv.
|
Shared
power to dispose or to direct the disposition of:
|
|
1,206,001(2)
|
|
|
(1)
|
Includes (i) 508,679 shares of common stock, (ii) 457,917 shares of common stock underlying options and (iii) 41,216 shares of common stock underlying Class A Warrants and (iv) 61,823 shares of common stock underlying Class B Warrants held by Dr. Ianchulev directly that are exercisable within 60 days of the date of this report.
|
|
|
(2)
|
Includes (i) 6,000 shares of Common Stock held by the
Meliora Trust, (ii) 606,667 shares of Common Stock and 140,000 shares of Common Stock underlying options held by PME that are
exercisable within 60 days of the date of this report and (iii) 453,334 shares of Common Stock held by PME Investor Services Eyenovia,
LLC. Dr. Ianchulev is one of the two principal shareholders of PME and a manager of PME Investor Services Eyenovia, LLC and, therefore,
may be deemed to have beneficial ownership of the shares of Common Stock held by PME and PME Investor Services Eyenovia, LLC.
|
|
CUSIP No. 30234E 104
|
Page 6 of 7 Pages
|
Curt LaBelle
|
a)
|
|
Amount beneficially owned: 1,417,662
|
|
Percentage:
6.8%
|
|
b)
|
|
Number of shares to which the Reporting Person has:
|
|
|
|
|
i.
|
Sole power to vote or to direct the vote:
|
|
217,661(1)
|
|
|
ii.
|
Shared power to vote or to direct the vote:
|
|
1,200,001(2)
|
|
|
iii.
|
Sole power to dispose or to direct the disposition of:
|
|
217,661(1)
|
|
|
iv.
|
Shared power to dispose or to direct the disposition of:
|
|
1,200,001(2)
|
|
|
(1)
|
Includes 27,985 shares of Common Stock and 189,676 shares of Common Stock underlying options held by Dr. LaBelle directly that are exercisable within 60 days of the date of this report.
|
|
|
(2)
|
Includes (i) 606,667 shares of Common Stock and 140,000 shares of Common Stock underlying options held by PME that are exercisable within 60 days of the date of this report and (ii) 453,334 shares of Common Stock held by PME Investor Services Eyenovia, LLC. Dr. LaBelle is one of the two principal shareholders of PME and a manager of PME Investor Services Eyenovia, LLC and, therefore, may be deemed to have beneficial ownership of the shares of Common Stock held by PME and PME Investor Services Eyenovia, LLC.
|
Private Medical Equity, Inc.
|
a)
|
|
Amount beneficially owned: 746,667
|
|
Percentage:
3.6%
|
|
b)
|
|
Number of shares to which the Reporting Person has:
|
|
|
|
|
i.
|
Sole power to vote or to direct the vote:
|
|
746,667(1)
|
|
|
ii.
|
Shared power to vote or to direct the vote:
|
|
0
|
|
|
iii.
|
Sole power to dispose or to direct the disposition of:
|
|
746,667(1)
|
|
|
iv.
|
Shared power to dispose or to direct the disposition of:
|
|
0
|
|
|
(1)
|
Includes 606,667 shares of Common Stock and 140,000 shares of Common Stock underlying options held by PME that are exercisable within 60 days of the date of this report.
|
(c) Each of the required transactions described in this Item
5(a) were reported on a Form 4 filed by Dr. Ianchulev with the SEC pursuant to Section 16 of the Act and are available on the SEC’s
website at www.sec.gov. The information reported in such filings is expressly incorporated herein.
|
Item 7.
|
Material to be Filed as Exhibits
|
|
Exhibit 99.1*
|
Joint Filing Agreement by and among the Reporting Persons.
|
|
_______
|
|
* Filed previously.
|
CUSIP No. 30234E 104
|
Page 7 of 7 Pages
|
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Date: August 14, 2020
|
/s/ Tsontcho Ianchulev
|
|
|
Tsontcho Ianchulev
|
|
Date: August 14, 2020
|
/s/ Curt LaBelle
|
|
|
Curt LaBelle
|
|
Date: August 14, 2020
|
Private Medical Equity, Inc.
|
|
|
|
|
|
|
By:
|
/s/ Tsontcho Ianchulev
|
|
|
|
Name: Tsontcho Ianchulev
|
|
|
|
Title: Member
|
|
|
By:
|
/s/ Curt LaBelle
|
|
|
|
Name: Curt LaBelle
|
|
|
|
Title: Member
|
|
|
|
|
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
